Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial
Aflibercept 8 mg was effective and well tolerated in Asian patients with nAMD, with demonstrated improvements in functional and anatomic outcomes comparable to aflibercept 2 mg at W48. Aflibercept 8 mg outcomes were achieved with fewer injections than with aflibercept 2 mg, consistent with overall PULSAR results.
Authors
- Zoran Hasanbasic (ORCID: https://orcid.org/0000-0003-0673-012X)
- Ursula Schmidt-Ott
- Andrea Schulze
- Xin Zhang (ORCID: https://orcid.org/0000-0001-5008-0879)
- Timothy Y. Y. Lai
- Shih-Jen Chen
- Min Zhao
- Tomohiro Iida
- Sergio Leal
- Tien Y Wong (ORCID: https://orcid.org/0000-0002-8448-1264)
- Andrew Chang
- Won Ki Lee
- Xiaodong Sun
- Chui Ming Gemmy Cheung
Institutions
- Chinese University of Hong Kong (HK)
- Singapore National Eye Center (SG)
- Taipei Veterans General Hospital (TW)
- Bayer (Australia) (AU)
- Singapore Eye Research Institute (SG)
- Bayer (Switzerland) (CH)
- Nune Eye Hospital (KR)
- Shanghai First People's Hospital (CN)
- Tokyo Women's Medical University (JP)
- Bayer (China) (CN)
- Retina Clinic (BR)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Asia-Pacific Journal of Ophthalmology
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1016/j.apjo.2026.100278
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00